Abstract: A transdermal drug delivery system for the topical application of one or more active agents contained in one or more polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric backing layer which can control the delivery rate and profile of the transdermal drug delivery system by adjusting the moisture vapor transmission rate of the polymeric backing layer.
Type:
Application
Filed:
July 21, 2014
Publication date:
June 11, 2015
Applicant:
Noven Pharmaceuticals, Inc.
Inventors:
David Kanios, Juan A. Mantelle, Viet Nguyen
Abstract: A transdermal delivery system is provided where the drug delivery rates, onset and profiles of at least one active agent are controlled by selectively manipulating the monomeric make up of an acrylic-based polymer in the transdermal drug delivery system. The drug carrier composition may be comprised of (a) one or more acrylic-based polymers having one or more different monomers selected from the group consisting of hard and soft monomers; (b) one or more silicone-based polymers; and (c) one or more active agents where the device provides a desired solubility for the active agent and controls drug delivery rates, onset and profiles of at least one active agent.
Abstract: Compositions for the transdermal delivery of amphetamine in a flexible, finite form are described. The compositions comprise a polymer matrix that includes amphetamine or a pharmaceutically acceptable salt or prodrug thereof and a backing layer comprising a polyurethane film layer and a polyester film layer, with a polyurethane adhesive disposed therebetween. Related methods also are described.
Abstract: Described are transdermal drug delivery compositions comprising amphetamine, methods of manufacturing transdermal drug delivery compositions comprising amphetamine, and therapeutic methods using transdermal drug delivery compositions comprising amphetamine, such as may be desired for achieving central nervous system stimulation, such as for the treatment of attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), or for the treatment of narcolepsy. In some embodiments, the compositions comprise an amount of polyurethane effective to control the presence of and/or prevent the formation of phenyl acetone in the compositions. The polyurethane may be present in a drug-containing polymer matrix or in a backing adjacent the drug-containing polymer matrix.
Type:
Application
Filed:
December 19, 2014
Publication date:
April 16, 2015
Applicant:
Noven Pharmaceuticals, Inc.
Inventors:
Viet Nguyen, Steven DINH, Jun LlAO, Robert L. LAMBERT
Abstract: A transdermal delivery system is provided where the drug delivery rates, onset and profiles of at least one active agent are controlled by selectively manipulating the monomeric make up of an acrylic-based polymer in the transdermal drug delivery system. The drug carrier composition may be comprised of (a) one or more acrylic-based polymers having one or more different monomers selected from the group consisting of hard and soft monomers; (b) one or more silicone-based polymers; and (c) one or more active agents where the device provides a desired solubility for the active agent and controls drug delivery rates, onset and profiles of at least one active agent.
Abstract: Described are transdermal drug delivery compositions comprising amphetamine, methods of making transdermal drug delivery compositions comprising amphetamine, and therapeutic methods of using them. In specific embodiments, the compositions are free of components with moieties that are reactive with amphetamine. In specific embodiments, the compositions are manufactured using solvents free of components with moieties that are reactive with amphetamine. Therapeutic methods using the compositions also are described.
Abstract: A blend of at least two polymers in combination with a drug provides a pressure-sensitive adhesive composition for a transdermal drug delivery system in which the drug is delivered from the pressure-sensitive adhesive composition and through dermis when the pressure-sensitive adhesive composition is in contact with human skin.
Abstract: Disclosed is a transdermal composition for delivery of diclofenac comprising the use of a pharmaceutically acceptable acid or salt form in an admixture with a pharmaceutically acceptable adhesive matrix carrier. In a preferred embodiment, diclofenac is present as the free acid and potassium salt form in the adhesive matrix composition together with a dual permeation enhancer. The adhesive matrix composition is applied in a method of substantially increasing drug delivery for 24 or more hours.
Abstract: A transdermal delivery system is provided where the drug delivery rates, onset and profiles of at least one active agent are controlled by selectively manipulating the monomeric make up of an acrylic-based polymer in the transdermal drug delivery system. The drug carrier composition may be comprised of (a) one or more acrylic-based polymers having one or more different monomers selected from the group consisting of hard and soft monomers; (b) one or more silicone-based polymers; and (c) one or more active agents where the device provides a desired solubility for the active agent and controls drug delivery rates, onset and profiles of at least one active agent.
Abstract: Described are transdermal drug delivery systems for the transdermal administration of tertiary amine drugs, such as rivastigmine, fentanyl or rotigotine, comprising a polymer matrix comprising a free base form of the drug and at least one carboxyl group-containing compound. In some embodiments, the systems include a rate-controlling membrane and a skin-contacting face adhesive apart from the polymer matrix.
Type:
Application
Filed:
March 13, 2014
Publication date:
September 18, 2014
Applicant:
NOVEN PHARMACEUTICALS, INC.
Inventors:
Jun Liao, Takito Shima, Puchun Liu, Steven Dinh
Abstract: Transdermal drug delivery systems comprising a drug-containing layer, a backing layer, and an occlusive overlay layer extending beyond the perimeter of the backing layer by 3 to 6 mm in all directions are described. The systems achieve increased drug delivery over an extended time period.
Abstract: Described are transdermal drug delivery compositions comprising amphetamine, methods of making them and therapeutic methods using them. The compositions are provided in a flexible, finite form (e.g. “patch”-type systems) and comprise a polymer matrix that includes amphetamine and an acrylic block copolymer.
Abstract: Described herein are transdermal compositions comprising methylphenidate in a polymer matrix comprising a non-reactive random acrylic polymer and an acrylic block copolymer. Method of making such compositions, and therapeutic methods using them also are disclosed.
Abstract: Transdermal compositions comprising methylphenidate in a polymer matrix comprising a rubber-based pressure-sensitive adhesive are disclosed, such as a polymer matrix comprising styrene-isoprene-styrene or polyisobutylene polymers. Method of making such compositions, and therapeutic methods using them also are disclosed.
Abstract: A transdermal delivery system is provided where the drug delivery rates, onset and profiles of at least one active agent are controlled by selectively manipulating the monomeric make up of an acrylic-based polymer in the transdermal drug delivery system. The drug carrier composition may be comprised of (a) one or more acrylic-based polymers having one or more different monomers selected from the group consisting of hard and soft monomers; (b) one or more silicone-based polymers; and (c) one or more active agents where the device provides a desired solubility for the active agent and controls drug delivery rates, onset and profiles of at least one active agent.
Abstract: A transdermal delivery system is provided for the topical application of one or more active agents contained in one or more polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric and/or adhesive coating that is applied to either the transdermal system's backing or release liner. The transdermal delivery device is manufactured to optimize drug loading while providing desirable adhesion to skin or mucosa as well as providing modulation of the drug delivery and profile.
Type:
Application
Filed:
February 27, 2014
Publication date:
August 28, 2014
Applicant:
Noven Pharmaceuticals, Inc.
Inventors:
David Kanios, Rod Hartwig, Juan Mantelle, David W. Houze
Abstract: A transdermal drug delivery system for the topical application of one or more active agents contained in one or more polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric backing layer which can control the delivery rate and profile of the transdermal drug delivery system by adjusting the moisture vapor transmission rate of the polymeric backing layer.
Type:
Grant
Filed:
December 29, 2010
Date of Patent:
August 26, 2014
Assignee:
Noven Pharmaceuticals, Inc.
Inventors:
David Kanios, Juan A. Mantelle, Viet Nguyen
Abstract: Described are transdermal drug delivery systems for the transdermal administration of levonorgestrel, comprising a polymer matrix and levonorgestrel acetate. Methods of making and using such systems also are described.
Abstract: A drug delivery device initially having two adhesive layers containing at least one active agent in each layer are kept separate from each other prior to administration of the active agent. At the time of administration, the separated layers are combined to form a dual layer adhesive transdermal drug delivery device which results in the administration of the at least one active compound after topical application of the device.
Abstract: Described are transdermal drug delivery systems for the transdermal administration of estrogen, comprising a polymer matrix and estrogen. Methods of making and using such systems also are described.